BrainsWay Ltd. reports developments in noninvasive neurostimulation treatments for mental health disorders. The company markets its proprietary Deep TMS platform, with FDA-cleared indications that include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, and derives revenue from leases and sales of Deep TMS systems.
Recurring updates include financial results, operating guidance, system placements, reimbursement and payer coverage for TMS therapy, clinical data for Deep TMS protocols such as SWIFT, and additional regulatory clearances. Company news also covers strategic minority-stake and milestone-based investments in mental health providers and related neurostimulation technologies, along with investor conference participation and operational updates across its U.S. and Israel-based business.
BrainsWay (BWAY) announced a collaboration with Inland Psychiatric Medical Group that includes an order for multiple Deep TMS systems. The systems are planned for installation at IPMG clinics in Southern California. The collaboration also includes exploring scientific, clinical and research projects aimed at expanding applications of interventional psychiatry and mental health care.
IPMG provides psychiatry, medication management, psychotherapy, TMS therapy, esketamine treatment and clinical research. BrainsWay’s Deep TMS, a treatment that uses magnetic pulses to stimulate brain networks, is currently FDA-cleared for major depressive disorder with and without anxiety symptoms, obsessive-compulsive disorder and smoking addiction.
BrainsWay (BWAY) announced expanded U.S. medical policy coverage for its SWIFT Accelerated Deep TMS protocol, a noninvasive brain stimulation treatment.
Over 70 million covered lives in the U.S. now have access to policies covering SWIFT. Favorable policy changes also extend to Deep TMS generally, including treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay said it continues educating stakeholders about Deep TMS with the goal of increasing coverage and patient access to care.
BrainsWay (BWAY) reported peer-reviewed pilot-study results of its Deep TMS technology in patients with Major Depressive Disorder and early-stage Alzheimer’s disease.
The 12-patient study delivered 36 Deep TMS sessions using the H1 and H7 coils and showed an 83.3% response rate (≥50% PHQ‑9 reduction) and a 50% remission rate (PHQ‑9 ≤4) in depressive symptoms. Quantitative EEG analyses indicated reduced delta power in the right temporal lobe and increased alpha coherence between several frontal and temporal sites, suggesting modulation of brain activity and connectivity patterns linked to Alzheimer’s disease. Results were published in the Journal of Geriatric Psychiatry and Neurology, and BrainsWay stated that further controlled clinical research is required. Deep TMS is not FDA‑cleared for treating Alzheimer’s disease.
BrainsWay (NASDAQ & TASE: BWAY) reported new peer-reviewed data from a secondary analysis of a multisite randomized trial of Deep TMS in Major Depressive Disorder, published in the Journal of Affective Disorders. The analysis showed that, among 89 patients, those exhibiting suicidal ideation (SSI>0) fell from 22.5% (20/89) at baseline to 6.7% (6/89) after 6 weeks, a 70% relative reduction. Median time to improvement in suicidality was 10 days with the SWIFT accelerated Deep TMS protocol versus 13 days with the standard once-daily protocol, a statistically significant difference. According to BrainsWay, these findings align with other 2026 publications suggesting TMS is associated with reduced suicidal ideation, though Deep TMS is FDA-cleared only for MDD, not for treating or preventing suicidal ideation or behavior.
BrainsWay (NASDAQ & TASE: BWAY) reported record Q2 2026 revenue of $17.1 million, up 35% year-over-year, with operating income rising to $2.4 million and net income to $2.7 million. Adjusted EBITDA increased 141% to $3.5 million, reflecting a 20% margin.
The company shipped a record 125 Deep TMS systems in the quarter, a 42% increase, bringing the installed base to about 1,949. Remaining performance obligations grew 30% to $80.4 million. BrainsWay generated $6.3 million in operating cash flow and held about $62.4 million in cash and restricted cash at June 30, 2026.
For full-year 2026, BrainsWay raised revenue guidance to $68–$70 million and Adjusted EBITDA guidance to $13–$14 million, implying anticipated revenue growth of roughly 30%–34% and Adjusted EBITDA growth of about 90%–100% versus 2025.
BrainsWay (NASDAQ & TASE: BWAY) will report its second quarter 2026 financial results and operational highlights before U.S. market open on Wednesday, August 12, 2026. An English conference call and webcast will be held at 8:30 AM Eastern Time, with a separate Hebrew webcast on Thursday, August 13, 2026 at 11:00 AM Israeli Daylight Time. The English webcast replay will be available for 30 days on BrainsWay’s investor relations website.
BrainsWay (NASDAQ & TASE: BWAY) announced a $3 million strategic minority equity investment in Radial Health, a management services organization supporting a nationwide network of Brain Medicine clinics, as part of Radial's previously announced Series A financing round.
According to BrainsWay, Radial develops clinical infrastructure, reimbursement tools, and an AI-guided decision support platform to support noninvasive Brain Medicine treatments such as Deep TMS and other therapies. The company said this investment aligns with its strategy to take minority stakes in high-performing mental health provider networks to broaden awareness and access to advanced, evidence-based psychiatric care.
BrainsWay (NASDAQ & TASE: BWAY) announced a strategic minority-stake investment in Sound Minds Behavioral, an outpatient behavioral health platform with locations across Connecticut, Pennsylvania, New Jersey and New York. BrainsWay will invest $500,000 in Sound Minds through a preferred, annually compounding security.
According to BrainsWay, the deal supports its strategy of partnering with growth-oriented mental health providers to expand access to interventional psychiatry and innovative, evidence-based care. The transaction was executed with CM Counsel Management LLC, d/b/a Sound Minds Behavioral, with S. Friedman, Abramson & Co. Law Offices advising BrainsWay.
BrainsWay (NASDAQ:BWAY) reported positive real-world data from the largest analysis of Deep TMS in patients with comorbid PTSD and major depressive disorder.
The retrospective study of 462 patients showed 83.5% PTSD response, 66.6% depression response, 27.3% remission, and around 50% average symptom reductions. Deep TMS is not FDA-cleared for PTSD and findings are preliminary.
BrainsWay (NASDAQ & TASE: BWAY) reported expanded U.S. medical policy coverage for its SWIFT™ Accelerated Deep TMS™ protocol. A new policy in South Carolina adds 2 million members, and eight major payers plus the US Department of Veterans Affairs now support accelerated TMS approaches.
These payers represent over 57 million covered lives, including coverage expansions for Deep TMS in major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). BrainsWay highlights supporting clinical evidence, its proprietary H-coil technology, and collaborations with providers and policymakers to further broaden access.